90 related articles for article (PubMed ID: 9430475)
1. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
Horak E; Hartmann F; Garmestani K; Wu C; Brechbiel M; Gansow OA; Landolfi NF; Waldmann TA
J Nucl Med; 1997 Dec; 38(12):1944-50. PubMed ID: 9430475
[TBL] [Abstract][Full Text] [Related]
2. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas.
Coliva A; Zacchetti A; Luison E; Tomassetti A; Bongarzone I; Seregni E; Bombardieri E; Martin F; Giussani A; Figini M; Canevari S
Cancer Immunol Immunother; 2005 Dec; 54(12):1200-13. PubMed ID: 15926078
[TBL] [Abstract][Full Text] [Related]
3. Quantitative autoradiographic evaluation of the influence of protein dose on monoclonal antibody distribution in human ovarian adenocarcinoma xenografts.
Yang FE; Brown RS; Koral KF; Clavo AC; Jackson GA; Wahl RL
Cancer Immunol Immunother; 1992; 35(6):365-72. PubMed ID: 1394341
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.
Song H; Hobbs RF; Vajravelu R; Huso DL; Esaias C; Apostolidis C; Morgenstern A; Sgouros G
Cancer Res; 2009 Dec; 69(23):8941-8. PubMed ID: 19920193
[TBL] [Abstract][Full Text] [Related]
5. CD46 targeted
Li J; Huang T; Hua J; Wang Q; Su Y; Chen P; Bidlingmaier S; Li A; Xie Z; Bidkar AP; Shen S; Shi W; Seo Y; Flavell RR; Gioeli D; Dreicer R; Li H; Liu B; He J
J Exp Clin Cancer Res; 2023 Mar; 42(1):61. PubMed ID: 36906664
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of HER2-Targeted Intraperitoneal
Chung SK; Vargas DB; Chandler CS; Katugampola S; Veach DR; McDevitt MR; Seo SH; Vaughn BA; Rinne SS; Punzalan B; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Yang G; Ouerfelli O; Nash GM; Cercek A; Fung EK; Howell RW; Larson SM; Cheal SM; Cheung NV
J Nucl Med; 2023 Sep; 64(9):1439-1445. PubMed ID: 37348919
[TBL] [Abstract][Full Text] [Related]
7. Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003.
Maaland AF; Saidi A; Torgue J; Heyerdahl H; Stallons TAR; Kolstad A; Dahle J
PLoS One; 2020; 15(3):e0230526. PubMed ID: 32187209
[TBL] [Abstract][Full Text] [Related]
8.
Li M; Sagastume EA; Lee D; McAlister D; DeGraffenreid AJ; Olewine KR; Graves S; Copping R; Mirzadeh S; Zimmerman BE; Larsen RH; Johnson FL; Schultz MK
Curr Med Chem; 2020; 27(41):7003-7031. PubMed ID: 32720598
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma.
Westrøm S; Bønsdorff TB; Abbas N; Bruland ØS; Jonasdottir TJ; Mælandsmo GM; Larsen RH
PLoS One; 2016; 11(10):e0165382. PubMed ID: 27776176
[TBL] [Abstract][Full Text] [Related]
10. Biological effect of lead-212 localized in the nucleus of mammalian cells: role of recoil energy in the radiotoxicity of internal alpha-particle emitters.
Azure MT; Archer RD; Sastry KS; Rao DV; Howell RW
Radiat Res; 1994 Nov; 140(2):276-83. PubMed ID: 7938477
[TBL] [Abstract][Full Text] [Related]
11. Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration.
Adams GP; McCartney JE; Wolf EJ; Eisenberg J; Tai MS; Huston JS; Stafford WF; Bookman MA; Houston LL; Weiner LM
Cancer Immunol Immunother; 1995 May; 40(5):299-306. PubMed ID: 7600561
[TBL] [Abstract][Full Text] [Related]
12. Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.
Lindegren S; Andrade LN; Bäck T; Machado CM; Horta BB; Buchpiguel C; Moro AM; Okamoto OK; Jacobsson L; Cederkrantz E; Washiyama K; Aneheim E; Palm S; Jensen H; Tuma MC; Chammas R; Hultborn R; Albertsson P
PLoS One; 2015; 10(5):e0126298. PubMed ID: 25970341
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology and tissue disposition studies of 131I-labeled anticolorectal carcinoma human monoclonal antibody LiCO 16.88.
Rosenblum MG; Levin B; Roh M; Hohn D; McCabe R; Thompson L; Cheung L; Murray JL
Cancer Immunol Immunother; 1994 Dec; 39(6):397-400. PubMed ID: 8001027
[TBL] [Abstract][Full Text] [Related]
14. Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma.
Ludwig AD; Labadie KP; Seo YD; Hamlin DK; Nguyen HM; Mahadev VM; Yeung RS; Wilbur DS; Park JO
J Oncol; 2019; 2019():4564707. PubMed ID: 31636665
[TBL] [Abstract][Full Text] [Related]
15. Postural effects on peritoneal transport and systemic uptake of radiolabeled monoclonal antibodies.
Barrett JS; Fisher SJ; Wahl RL
Cancer Immunol Immunother; 1997 May; 44(3):173-8. PubMed ID: 9191877
[TBL] [Abstract][Full Text] [Related]
16. Towards translation of 212Pb as a clinical therapeutic; getting the lead in!
Yong K; Brechbiel MW
Dalton Trans; 2011 Jun; 40(23):6068-76. PubMed ID: 21380408
[TBL] [Abstract][Full Text] [Related]
17. Early Normal Tissue Effects and Bone Marrow Relative Biological Effectiveness for an Actinium 225-Labeled HER2/neu-Targeting Antibody.
Liatsou I; Josefsson A; Yu J; Li Z; Davis K; Brayton C; Wang H; Hobbs RF; Sgouros G
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(4):1028-1037. PubMed ID: 37331568
[TBL] [Abstract][Full Text] [Related]
18. Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma.
Gabriel EM; Necela B; Bahr D; Vivekanandhan S; Shreeder B; Bagaria S; Knutson KL
Res Sq; 2024 Apr; ():. PubMed ID: 38645250
[TBL] [Abstract][Full Text] [Related]
19. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria.
Bettegowda C; Dang LH; Abrams R; Huso DL; Dillehay L; Cheong I; Agrawal N; Borzillary S; McCaffery JM; Watson EL; Lin KS; Bunz F; Baidoo K; Pomper MG; Kinzler KW; Vogelstein B; Zhou S
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15083-8. PubMed ID: 14657371
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy for Brain Metastases: The Potential for Inflammation as a Target of Choice.
Corroyer-Dulmont A; Jaudet C; Frelin AM; Fantin J; Weyts K; Vallis KA; Falzone N; Sibson NR; Chérel M; Kraeber-Bodéré F; Batalla A; Bardet S; Bernaudin M; Valable S
Front Oncol; 2021; 11():714514. PubMed ID: 34504791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
